Antisense strategies in neurobiology

Neurochemistry International

Volumn 31, Issue 3, 1997, Pages 321-348

  Weiss, Benjamin ^a   Davidkova, Genoveva ^a   Zhang, Sui Po ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CALMODULIN; COMPLEMENTARY RNA; DOPAMINE RECEPTOR; MESSENGER RNA; PLASMID VECTOR; PROTEIN; RECEPTOR SUBTYPE;

ANIMAL CELL; BIOCHEMISTRY; CELL STRAIN; GENE TARGETING; NERVOUS SYSTEM; NEUROBIOLOGY; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALIA;

EID: 0030855719     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(96)00105-2     Document Type: Article

References (187)

1. Acheson, A., Conover, J. C., Fandl, J. P., Di Chiara, T. M., Russel, M., Thadani, A., Squinto, S. P., Yancopoulous, G. D. and Lindsay, R. M. (1995) A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 374, 450-453.
2. Adams, J. U., Chen, X., DeRiel, J. K., Adler, M. W. and Liu-Chen, L.-Y. (1994) Intracerebroventricular treatment with an antisense oligodeoxynucleotide to k-opioid receptors inhibited k-agonist-induced analgesia in rats. Brain Res. 667, 129-132.
3. Agrawal, S., Temsamani, J., Galbraith, W. and Tang, J. (1995) Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16.
4. Albert, P. R. and Morris, S. J. (1994) Antisense knockouts: molecular scalpels for the dissection of signal transductions. Trends Pharmacol. Sci. 15, 250-254.
5. Amaratunga, A., Morin, P. J., Kosik, K. S. and Fine, R. E. (1993) Inhibition of kinesin synthesis and rapid antero-grade axonal transport in vivo by an antisense oligonucleotide. J. Biol. Chem. 268, 17427-17430.
6. Ambuhl, P., Gyurko, R. and Phillips, M. I. (1995) A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin ATI receptor. Regul. Pept. 59, 171-182.
7. Arany, I., Zhang, X., Loh, H. H. and Lee, N. M. (1992) Antisense proenkephalin cDNA transfection decreases opioid binding in NG 108-15 cells. Mol. Brain Res. 16, 295-302.
8. Baserga R. and Denhardt D. T. (eds.) (1992) Antisense strategies. In Annals of the New York Academy of Sciences, Vol. 660, Acad. Sci. NY.
9. 2, Glu4] deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid d receptor. Life Sci. 55, PL37-PL43.
10. Bonfils, E., Mendes, C., Roche, A. C., Monsigny, M. and Midoux, P. (1992) Uptake by macrophages of a biotinylated oligo-alpha-deoxythymidylate by using mannosylated streptavidin. Bioconj. Chem. 3, 277-284.
11. Bonner, T. I., Buckley, N. J., Young, A. C. and Brann, M. R. (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237, 527-531.
12. 6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol. Exptl. Therap. 274, 173-180.
13. Bozarth, M. A. (1989) New perspectives on cocaine addiction: recent findings from animal research. Can. J. Physiol. Pharmacol. 67, 1158-1167.
14. Budker, V. G., Knorre, D. G. and Vlassov, V. V. (1992) Cell membranes as barriers for antisense constructions. Antisense Res. Devl. 2, 177-184.
15. Burger, D. (1993) Novel antisense technology: therapeutic and diagnostic applications. J. Clin. Immunoassay 16,224-230.
16. Caceres, A. and Kosik, K. S. (1990) Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343, 461-463.
17. Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186.
18. Caron, M. and Lefkowitz, R. J. (1993) Catecholamine receptors: structure, function and regulation. Rec. Prog. Horm. Res. 48, 277-290.
19. Cha, X. Y., Xu, H., Rice, K. C., Porreca, F., Lai, J., Ananthan, S. and Rothman, R. B. (1995) Opioid peptide receptor studies. 1. Identification of a novel δ-opioid receptor binding site in rat brain membranes. Peptides 16, 191-198.
20. Chen, X. H., Adams, J. U., Geller, E. B., DeRiel, J. K., Adler, M. W. and Liu-Chen, L. Y. (1995) An antisense oligodeoxynucleotide to mu-opioid receptors inhibits muopioid receptor agonist-induced analgesia in rats. Eur. J. Pharmacol. 275, 105-108.
21. Chiasson, B. J., Hooper, M. L., Murphy, P. R. and Robertson, H. A. (1992) Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmacol. Mol. Pharmacol. 227, 451-453.
22. Chiasson, B. J., Armstrong, J. N., Hooper, M. L., Murphy, P. R. and Robertson, H. A. (1994) The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell. Mol. Neurobiol. 14, 507-522.
23. Cimino, M., Chen, J.-F. and Weiss, B. (1990) Ontogenetic development of calmodulin mRNA in rat brain using in situ hybridization histochemistry. Devl. Brain Res. 54, 43-49.
24. Citro, G., Perrotti, D., Cucco, C., D 'Agnano, I., Sacchi, A., Zupi, G. and Calabretta, B. (1992) Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligo-deoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 89, 7031-7035.
25. Civelli, O., Bunzow, J. R., Grandy, D. K., Zhou, Q.-Y. and Van Tol, H. H. M. (1991) Molecular biology of the dopamine receptors. Eur. J. Pharmacol. Mol. Pharmacol. 207, 277-286.
26. Cohen, J. S. (ed.) (1989) Oligodeoxynucleotides: antisense inhibitors of gene expression. In Topics in Molecular and Structural Biology. CRC Press Inc., Boca Raton, FL.
27. Cohen, J. S. (1991) Antisense oligodeoxynucleotides as antiviral agents. Antiviral Res. 16, 121-133.
28. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exptl. Therap. 267, 1181-1190.
29. Creese, I. and Snyder, S. H. (1980) Chronic neuroleptic treatment and dopamine receptor regulation. Adv. Biochem. Psychopharmacol. 24, 89-94.
30. Crooke, S. T. (1992) Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol 32, 329-376.
31. Crooke, S. T. (1995) Progress in antisense therapeutics. Hematol. Pathol. 9, 59-72.
32. Crooke, S. T. (1995b) Medical Intelligence Unit: Therapeutic Applications of Oligonucleotides. R. G. Landes Co., Austin, TX.
33. Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B. S., Cummins, L. L., Greig, M. J., Guinosso, C. J., Kornbrust, D., Manoharan, M., Sasmor, H. M., Schleich, T., Tivel, K. L. and Griffey, R. H. (1996) Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exptl. Therap. 277, 923-937.
34. Davidkova, G., Zhang, S.-P., Nichols, R. A. and Weiss, B. (1996) Reduced level of calmodulin in PC12 cells induced by stable expression of calmodulin antisense RNA inhibits cell growth and induces neunte outgrowth. Neuroscience 75, 1003-1019.
35. DeLorenzo, R. J. (1981) The calmodulin hypothesis of neurotransmission. Cell Calcium 2, 365-385.
36. De Mesmaeker, A., Haner, R., Martin, P. and Moser, H. E. (1995) Antisense oligonucleotides. Acc. Chem. Res. 28, 366-374.
37. Dolnick, B. J. (1991) Antisense agents in cancer research and therapeutics. Cancer Invest. 9, 185-194.
38. Dragunow, M., Lawlor, P., Chiasson, B. and Robertson, H. (1993) C-fos antisense generates apomorphine and amphetamine-induced rotation. Neuroreport 5, 305-306.
39. Ebadi, M. and Hama, Y. (1988) Dopamine, GABA, cholecystokinin and opioids in neuroleptic-induced tardive dyskinesia. Neurosci. Biobehav. Rev. 12, 179-187.
40. Eng, L. F. (1993) Current antisense nucleic acid strategies for manipulating neuronal and glial cells. Res. Publ.-Assoc. Res. Nerv. Mental Dis. 71, 293-310.
41. Fagarason, M. O., Aiello, F., Muegge, K., Durum, S. and Axelrod, J. (1990) Interleukin I induces beta-endorphin secretion via fos and jun in AtT-20 pituitary cells. Proc. Natl. Acad. Sci. U.S.A. 87, 7871-7874.
42. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chau, H. W., Weng, M., Northrop, G. M., Ringold, G. M. and Danielsa, G. A. (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84, 7413-7417.
43. Felgner, J. H., Kumar, K., Sridhar, C. N., Wheeler, C. J., Tsai, Y. J., Border, R., Ramsey, P., Martin, M. and Felgner, P. L. (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269, 2550-2561.
44. Ferrari, S., Manfredini, R. and Torelli, U. (1994) Antisense strategies in leukemia. Haematologica 79, 107-111.
45. Georgieva, J., Heilig, M., Nylander, I., Herrera-Marschitz, M. and Terenius, L. (1995) In vivo antisense inhibition of prodynorphin expression in rat striatum: dose-dependence and sequence specificity. Neurosci. Lett. 192, 69-71.
46. Gillardon, F., Beck, H., Uhlmann, E., Herdegen, T., Sandkühler, J., Peyman, A. and Zimmermann, M. (1994) Inhibition of c-fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion. Eur. J. Neurosci. 6, 880-884.
47. Gingrich, J. and Caron, M. (1993) Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16, 299-321.
48. Goodchild, J. (1991) Antisense antivirals. Antisense Res. Devl. 1, 361-364.
49. 2+-dependent phosphorylation of tyrosine hydroxylase. J. Biol. Chem. 263, 9542-9549.
50. Gura, T. (1995) Antisense has growing pains. Science 270, 575-577.
51. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49, 167-174.
52. Hait, W. N., Grais, C., Benz, C. and Cadman, E. (1985) Inhibition of growth of leukemic cells by inhibitors of calmodulin phenothiazines and mellitin. Cancer Chemother. Pharmacol. 14, 202-205.
53. Hanemaaijer, R. and Ginzburg, I. (1991) Involvement of mature tau isoforms in the stabilization of neurites in PC12 cells. J. Neurosci. Res. 30, 163-171.
54. Hardcastle, I., Rowlands, J., Houghton, J., Parr, I. B., Potter, G. A. and Jarman, J. (1995) Rationally designed analogs of tamoxifen with improved calmodulin antagonism. J. Med. Chem. 38, 241-248.
55. Harrison, P. J. and Burnet, P. W. J. (1994) Antisense as an explanatory, experimental and therapeutic tool for psychiatric disorders. Psychol. Med. 24, 275-279.
56. Heilig, M., Engel, J. A. and Söderpalm, B. (1993) C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. Eur. J. Pharmacol. 236, 339-340.
57. Helene, C. and Toulme, J. (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta 1049, 99-125.
58. Hertl, M., Neckers, L. M. and Katz, S. I. (1995) Inhibition of interferon-gamma-induced intracellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. J. Invest. Dermatol. 104, 813-818.
59. B receptors in rat cerebellar granule cells. J. Pharmacol. Exptl. Therap. 264, (1993)423-430.
60. Hooper, M. L., Chiasson, B. J. and Robertson, H. A. (1994) Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect. Neuroscience 63, 917-924.
61. Hulsey, M. G., Pless, C. M., White, B. D. and Martin, R. J. (1995) ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regul. Pept. 59, 207-214.
62. Idänpään-Heikkilä, J., Rauhala, P. and Männistö, P. (1995) Mu-and delta-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats. Eur. J. Pharmacol. 284, 227-230.
63. Ivins, K. J., Neve, K. A., Feller, D. J., Fidel, S. A. and Neve, R. L. (1993) Antisense GAP-43 inhibits the evoked release of dopamine from PC12 cells. J. Neurochem. 60, 626-633.
64. Jap Tjoen San, E. R. A., Schmidt-Michels, M., Oestreicher, A. B., Gispen, W. H. and Schotman, P. (1992) Inhibition of nerve growth factor-induced B-50/GAP-43 expression by antisense oligomers interferes with neunte outgrowth of PC12 cells. Biochem. Biophys. Res. Commun. 187, 839-846.
65. Juliano, R. L. and Akhtar, S. (1992) Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Devl. 2, 165-176.
66. Kebabian, J. and Calne, D. (1979) Multiple receptors for dopamine. Nature 277, 93-98.
67. Kirsch, J., Wolters, I., Triller, A. and Betz, H. (1993) Gephyrin antisense oligonucleotides prevent glycine receptor clustering in spinal neurons. Nature 366, 745-748.
68. Knorre, D. G., Vlassov, V. V., Zarytova, V. F., Lebedev, A. V. and Federova, O. S. (1994) Design and Targeted Reactions of Oligonucleotide Derivatives. CRC Press Inc., Boca Raton, FL..
69. 2-agonist antinociception. Neuro-report 5, 1049-1052.
70. Lai, J., Bilsky, E. J. and Porreca, F. (1995) Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. J. Recept. Res. 15, 643-650.
71. 1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J. Neurosci. 15, 4250-4258.
72. Laptev, A., Lu, Z., Colige, A. and Prockop, D. (1994) Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA. Biochemistry 33, 11033-11039.
73. Lazo, J. S., Chen, D.-L., Gallichio, N. S. and Hait, W. N. (1986) Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells. Cancer Res. 46, 2236-2240.
74. Lefkowitz, R. J., Cotecchia, S., Kjelsberg, M. A., Pitcher, J., Koch, W. J., Inglese, J. and Caron, M. (1993) Adrenergic receptors: recent insights into their mechanism of activation and desensitization. Adv. Sec. Mess. Phosphoprotein Res. 28, 1-9.
75. Leonetti, J., Degols, G., Clarenc, J., Mechti, N. and Lebleu, B. (1993) Cell delivery and mechanisms of action of antisense oligonucleotides. Progr. Nucl. Acids Res. Mol. Biol. 44, 143-154.
76. 1-Rs and angiotensin II action in astroglial and neuronal cells in primary cultures from the brain. Proc. Natl. Acad. Sci. U.S.A. 92, 1162-1166.
77. Lu, D. and Raizada, M. K. (1995) Delivery of angiotensin II type 1 receptor antisense inhibits angiotensin action in neurons from hypertensive rat brain. Proc. Natl. Acad. Sci. U.S.A. 92, 2914-2918.
78. Majocha, R. E., Agrawal, S., Tang, J.-Y., Humke, E. W. and Marotta, C. A. (1994) Modulation of the PC12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor protein. Cell. Mol. Neurobiol. 14, 425-438.
79. Malcolm, A. D., Coulson, J., Blake, N. and Archard, L. C. (1992) Applications of antisense oligodeoxynucleotides in virology. Biochem. Soc. Trans. 20, 762-764.
80. Malmberg, A., Jackson, D. M., Eriksson, A. and Mohell, N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol. Pharmacol. 43, 749-754.
81. Maurer, R. A. (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294, 94-97.
82. McCarthy, M. M., Brooks, P. J., Pfaus, J. G., Brown, H. E., Flanagan, L. M., Schwartz-Giblin, S. and Pfaff, D. W. (1993) Antisense oligodeoxynucleotides in behavioral neuroscience. Neuroprotocols 2, 67-74.
83. McCarthy, M. M., Schlenker, E. H. and Pfaff, D. W. (1993) Enduring consequences of neonatal treatment with antisense oligodeoxynucleotides to estrogen receptor messenger ribonucleic acid on sexual differentiation of rat brain. Endocrinology 133, 433-439.
84. McCarthy, M. M., Kleopoulos, S. P., Mobbs, C. V. and Pfaff, D. W. (1994) Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen-induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology 59, 432-440.
85. 67 mRNAs modulate reproductive behavior in the female rat. Brain Res. 636, 209-220.
86. McCarthy, M. M., Nielsen, D. A. and Goldman, D. (1995) Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brain. Regul. Pept. 59, 163-170.
87. Means, A. (1994) Calcium, calmodulin and cell cycle regulation. FEBS Lett. 347, 1-4.
88. Meeker, R., LeGrand, G., Ramirez, J., Smith, T. and Shih, Y.-H. (1995) Antisense vasopressin oligonucleotides: uptake, turnover, distribution, toxicity and behavioral effects. J. Neuroendocrinol. 7, 419-428.
89. Melino, G., Annicchiarico-Petruzzelli, M., Piredda, L., Candi, E., Gentile, V., Davies, P. J. A. and Piacentini, M. (1994) Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol. Cell. Biol. 14, 6584-6596.
90. 1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin. Regul. Pept. 54, 543-551.
91. Milligan, J., Matteuci, M. and Martin, J. (1993) Current concepts in antisense drug design. J. Med. Chem. 36, 1836-1923.
92. Morris, M., Callahan, M. F., Li, P. and Lucion, A. B. (1995) Central oxytocin mediates stress-induced tachycardia. J. Neuroendocrinol. 7, 455-459.
93. Murphy, P. R., Sato, Y. and Knee, R. S. (1992) Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line. Mol. Endocrinol. 6, 877-884.
94. Murray, J. A. H. (ed.) (1994) Antisense RNA and DNA. In Modern Cell Biology. Vol. 11, Wiley-Liss Inc., New York, NY.
95. Narita, M. and Tseng, L. F. (1995) Stimulation of spinal δ-opioid receptors in mice selectively enhances the attenuation of δ-opioid receptor-mediated antinociception by antisense oligodeoxynucleotide. Eur. J. Pharmacol. 284, 185-189.
96. Neckers, L. M., Rosolen, A. and Whitesell, L. (1992) Antisense inhibition of gene expression: a tool for studying the role of NMYC in the growth and differentiation of neuroectoderm-derived cells. J. Immunother. 12, 162-166.
97. Neve, R. L. (1993) Adenovirus enters the brain. Trends Neurosci. 16, 251-253.
98. 3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport 6, 573-576.
99. Niznik, H. B. (1987) Dopamine receptors: molecular structure and function. Mol. Cell. Endocrinol. 54, 1-8.
100. O'Dell, S. J., LaHoste, G. J., Wildmark, C. B., Shapiro, R. M., Potkin, S. G. and Marshall, J. F. (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in brain. Synapse 6, 146-153.
101. Ogawa, S., Olazábal, U. E., Parhar, I. S. and Pfaff, D. W. (1994) Effects of intrahypothalamic administration of antisense DNA for progesterone receptor mRNA on reproductive behavior and progesterone receptor immunoreactivity in female rat. J,.Neurosci. 14, 1766-1774.
102. Ogo, H., Hirai, Y., Miki, S., Nishio, H., Akiyama, M. and Nakata, Y. (1994) Modulation of substance P/neurokinin-1 receptor in human astrocytoma cells by antisense oligodeoxynucleotides. Gen. Pharmacol. 25, 1131-1135.
103. Osen-Sand, A., Catsicas, M., Staple, J. K., Jones, K. A., Ayala, G., Knowles, J., Grenningloh, G. and Catsicas, S. (1993) Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. Nature 364, 445-448.
104. Pakzaban, P., Geller, A. I. and Isacson, O. (1994) Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain. Human Gene Ther. 5, 987-995.
105. 3 rat pituitary tumor cells: evidence obtained by the use of antisense RNA inhibition and immunoblocking of the stimulatory guanine-nucleotide-binding protein. Eur. J. Biochem. 204, 413-418.
106. Perez, J. R., Li, Y., Stein, C. A., Majumder, S., van Orschot, A. and Narayanan, R. (1994) Sequence independent induction of Sp1 transcription factor activity by phosphorothioate oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 91, 5959-5961.
107. 3H]-spiroperidol by chronic treatment with the antidepressant amitriptyline. J. Pharmacol. Exptl. Therap. 215, 582-587.
108. Persaud, S. J. and Jones, P. M. (1994) Antisense oligonucleotide inhibition of gene expression: application to endocrine systems. J. Mol. Endocrinol. 12, 127-130.
109. Pierga, J.-Y. and Magdelenat, H. (1994) Applications of antisense oligonucleotides in oncology. Cell. Mol. Biol. 40, 237-261.
110. Pilowsky, P. M., Suzuki, S. and Minson, J. B. (1994) Antisense oligonucleotides: a new tool in neuroscience. Clin. Exp. Pharmacol. Physiol. 21, 935-944.
111. Pizzi, M., Valerio, A., Arrighi, V., Galli, P., Belloni, M., Ribola, M., Alberici, A., Spano, P. and Memo, M. (1995) Inhibition of glutamate-induced neurotoxicity by a tau antisense oligonucleotide in primary culture of rat cerebellar granule cells. Eur. J. Neurosci. 7, 1603-1613.
112. Pollio, G., Xue, P., Zanisi, M., Nicolin, A. and Maggi, A. (1993) Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats. Mol. Brain Res. 19, 135-139.
113. Pugh, M. T., O'Boyle, K. M., Molloy, A. G. and Waddington, J. L. (1985) Effects of the putative D-1 antagonist SCH 23390 on stereotyped behavior induced by the D-2 agonist RU 24213. Psychopharmacology 87, 308-312.
114. 2 dopamine receptors. Mol. Pharmacol. 48, 730-737.
115. Raffa, R. B., Martinez, R. P. and Connelly, C. D. (1994) G-protein antisense oligodeoxyribonucleotides and μ-opioid supraspinal antinociception. Eur. J. Pharmacol. 258, R5-R7.
116. Ridet, J.-L. and Privat, A. (1995) Gene therapy in the central nervous system: direct versus indirect gene delivery. J. Neurosci. Res. 42, 287-293.
117. Riederer, P., Lange, K. W., Kornhuber, J. and Danielczyk, W. (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arznemittel-Forschung 42, 265-268.
118. Roessler, B. and Davidson, B. (1994) Direct plasmid mediated transmission of adult murine brain cells in vivo using cationic liposomes. Neurosci. Lett. 167, 5-10.
119. Roberts-Lewis, J. M., Cimino, M., Krause, R. G., Tyrrell, D. F. Jr., Davis, L. G., Weiss, B. and Lewis, M. E. (1990) Anatomical localization of calmodulin mRNA in the rat brain with cloned cDNA and synthetic oligonucleotide probes. Synapse 5, 247-254.
120. Rosolen, A., Whitesell, L., Ikegaki, N., Kennett, R. and Neckers, L. M. (1991) Antisense inhibition of N-myc reduces cell growth but does not affect c-myc expression in the neuroepithelioma cell line CHP 100. Adv. Neuroblast. Res. 3, 29-36.
121. Rossi, G., Pan, Y.-X., Cheng, J. and Pasternak, G. W. (1994) Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54, PL375-PL379.
122. Rossi, G. C., Pan, Y. X., Brown, G. P. and Pasternak, G. W. (1995) Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett. 369, 192-196.
123. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A. 90, 8547-8551.
124. Sage, J. I. and Kark, M, H. (1994) Basic mechanisms of motor fluctuations. Neurology 44, S10-S14.
125. 1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 62, 2053-2056.
126. Salamone, J. D. (1992) Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes. Psychopharmacology 107, 160-174.
127. Salamone, J. D. (1994) The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61, 117-133.
128. Schaus, J. M., Kornfeld, E. C., Titus, R. D., Nichols, C. L., Huser, D. L., Clemens, J. A., Smalstig, E. B. and Fuller, R. W. (1993) Progress in the medicinal chemistry of dopaminergic agents. Drug Des. Disc. 9, 323-332.
129. Schlingensiepen, K.-H., Schlingensiepen, R., Kunst, M., Klinger, I., Gerdes, W., Seifert, W. and Brysch, W. (1993) Opposite functions of jun-E and c-jun in growth regulation and neuronal differentiation. Devl. Genet. 14, 305-312.
130. Schlingensiepen, K.-H., Wollnik, F., Kunst, M., Schlinensiepen, R., Herdegen, T. and Brysch, W. (1994) The role of jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell. Mol. Neurobiol. 14, 487-505.
131. Schwab, G., Duroux, I., Chavany, C. and Helene, C. (1994) An approach for new anticancer drugs: oncogene-targeted antisense DNA. Ann. Oncol. 4, 55-58.
132. Seeman, P. (1985) Brain dopamine receptors in schizophrenia and tardive dyskinesia. Psychopharmacology 2 (Suppl.), 2-8.
133. Shea, T. B., Beermann, M. L. and Fischer, I. (1993) Transient requirement for vimentin in neuritogenesis: intracellular delivery of anti-vimentin antibodies and antisense oligonucleotides inhibit neurite initiation but not elongation of existing neurites in neuroblastoma. J. Neurosci. Res. 36, 66-76.
134. 2 autoreceptors in the motor actions of cocaine. Mol. Pharmacol. 46, 51-57.
135. Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R. and Rosenberg, R. D. (1992) Antisense c-myb oligonucleotides inhibit smooth muscle cell accumulation in vivo. Nature 359, 67-70.
136. Simons, M. and Rosenberg, R. D. (1992) Antisense non-muscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. 70, 834-835.
137. Skutella, T., Montkowski, A., Stohr, T., Probst, J., Landgraf, R., Holsboehr, F. and Jirikowski, G. (1994) Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell. Mol. Neurobiol. 14, 579-587.
138. Skutella, T., Probst, J. C. D., Engelmann, M., Wotjak, C. T., Landgraf, R. and Jirikowski, G. F. (1994) Vasopressin antisense oligonucleotide induces temporary diabetes insipidus in rats. J. Neuroendocrinol. 6, 121-125.
139. Skutella, T., Probst, J. C. D., Jirikowski, G. F., Holsboer, F. and Spanagel, R. (1994) Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behavior in rats. Neurosci. Lett. 167, 55-58.
140. Sommer, W., Bjelke, B., Ganten, D. and Fuxe, K. (1993) Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. Neuroreport 5, 277-280.
141. Spano, P., Govoni, S. and Trabucci, M. (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv. Biochem. Psychopharmacol. 19, 155-161.
142. 2 receptor mRNAs in rat brain. J. Mol. Neurosci. 2, 155-161.
143. Standifer, K. M., Chien, C.-C., Wahlestedt, C., Brown, G. P. and Pasternak, G. W. (1994) Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron 12, 805-810.
144. Stein, C. A. and Cheng, Y.-C. (1993) Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?. Science 261, 1004-1012.
145. Sun, F.-Y. and Faden, A. (1995) Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 enhances survival and behavioral recovery following traumatic brain injury in rats. Brain Res. 693, 163-168.
146. Suzuki, S., Pilowsky, P., Minson, J., Arnolda, L., Llewellyn-Smith, I. and Chalmers, J. (1994) c-fos antisense in rostral ventral medulla reduces arterial blood pressure. Am. J. Physiol. 266, R1418-R1422.
147. Suzuki, S., Pilowsky, P., Minson, J., Arnolda, L., Llewellyn-Smith, I. and Chalmers, J. (1995) Antisense to thyrotropin releasing hormone receptor reduces arterial blood pressure in spontaneously hypertensive rats. Circul. Res. 77, 679-683.
148. 3 and autoreceptor preferring antagonist: effects on locomotor activity in the rat. Soc. Neurosci. 19, 89.
149. Takemoto, D. and Jilka, C. (1995) Increased content of calmodulin in human leukemia cells. Leuk. Res. 1983, 97-100.
150. Teichman-Weinberg, A., Littauer, U. Z. and Ginzburg, I. (1988) The inhibition of neunte outgrowth in PC12 cells by tubulin antisense oligodeoxyribonucleotides. Gene 72, 297-307.
151. Thermos, K. and Weiss, B. (1985) Calmodulin: function and pharmacological regulation. In Spasmophilia:Calcium Metabolism and Cell Physiology (Agnoli A., Canonico P., Milhaud G. and Scapagini U. Eds.), pp. 26-37. Libby, London.
152. Tischmeyer, W., Grimm, R., Schichnick, H., Brysch, W., Schlingensiepen, K. H. (1994) Sequence-specific impairment of learning by c-jun antisense oligonucleotides. Neuroreport 5, 1501-1504.
153. Torre, E., McNiven, M. A. and Urrutia, R. (1994) Dynamin 1 antisense oligonucleotide treatment prevents neurite formation in cultured hippocampal neurons. J. Biol. Chem. 269, 32411-32417.
154. Trojan, J., Blossey, B. K., Johnson, T. R., Rudin, S. D., Tykocinski, M., Ilan, J. and Ilan, J. (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. U.S.A. 89, 4874-4878.
155. Troy, C. M., Greene, L. A. and Shelanski, M. L. (1992) Neurite outgrowth in peripherin-depleted PC12 cells. J. Cell. Biol. 117, 1085-1092.
156. Tseng, L., Collins, K. and Kampine, J. (1994) Antisense oligodeoxynucleotide to a δ-opioid receptor selectively blocks the spinal antinociception induced by δ-, but not μ-or k-opioid receptor agonists in the mouse. Eur. J. Pharmacol. 258, R1-R3.
157. Uhlmann, E. and Peyman, A. (1990) Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90, 544-579.
158. Vaerman, J. L., Lammineur, C., Moureau, P., Lewalle, P., Deldime, F., Blumenfeld, M. and Martiat, P. (1995) BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86, 3891-3896.
159. Valerio, A., Alberici, A., Tinti, C., Spano, P. and Memo, M. (1994) Antisense strategy unravels a dopamine receptor distinct from the D2 subtype, uncoupled with adenylyl cyclase, inhibiting prolactin release from rat pituitary cells. J. Neurochem. 62, 1260-1266.
160. 5]enkephalin antiserum-sensitive enhancement of morphine antinociception. Neuroreport 5, 2601-2605.
161. 2. J. Neurochem. 64, 2765-2772.
162. Wahlestedt, C., Golanov, E., Yamamoto, S., Yee, F., Ericson, H., Yoo, H., Inturrisi, C. E. and Reis, D. J. (1993) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischemic infarctions. Nature 363, 260-263.
163. Wahlestedt, C., Pich, E. M., Koob, G. F., Yee, F. and Heilig, M. (1993) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259, 528-531.
164. Wahlestedt, C. (1994) Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15, 42-46.
165. Weiss, B. and Wallace, T. L. (1980) Mechanism and pharmacological implications of altering calmodulin activity. In Calcium and Cell Function (Cheung, W. Y. ed.), pp. 329-379. Academic Press, New York.
166. 2 messenger RNA. Neuroscience 55, 607-612.
167. Weiss, B., Zhou, L.-W. and Zhang, S.-P. (1994) Behavioral and molecular effects of dopamine receptor antisense oligodeoxynucleotides administered in vivo. Neuropsychopharmacology 10, 801S.
168. Weiss, B., Zhou, L.-W. and Zhang, S.-P. (1996a) Dopamine antisense oligodeoxynucleotides as potential novel tools for studying drug abuse. In Application of Antisense Strategies for Investigation of Receptor Mechanisms in vivo and in vitro (Raffa R. and Porreca F. eds.) R. G. Landes Co., Georgetown, TX, in press.
169. Weiss, B., Zhou, L.-W. and Davidkova, G. (1996b) Pharmacological and molecular regulation of gene expression of dopamine receptors. In Pharmacological Regulation of Gene Expression in the Central Nervous System (Merchant K. M. ed.), CRC Press, Boca Raton, FL, in press.
170. 2 dopamine receptor-mediated behaviors in mice. Coll. Prob. Drug Depend. p. 147.
171. Weiss, B., Zhang, S.-P. and Zhou, L.-W. (1997) Antisense strategies in dopamine receptor pharmacology. Life Sci. 60, 433-455.
172. Whitesell, L., Rosolen, A. and Neckers, L. M. (1991) Antisense suppression of N-myc expression inhibits the transdifferentiation of neuroectoderm tumor cell lines. Adv. Neuroblast. Res. 3, 45-54.
173. Wielbo, D., Sernia, C., Gyurko, R. and Phillips, M. I. (1995) Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25, 314-319.
174. 2 dopaminergic responses. Psychopharmacology 92, 285-291.
175. Wise, R. A. and Rompre, P.-P. (1989) Brain dopamine and reward. Annu. Rev. Psychol. 40, 191-225.
176. Woolf, T. M., Melton, D. A. and Jennings, C. G. B. (1992) Specificity of antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. U.S.A. 89, 7305-7309.
177. Yee, F., Ericson, H., Reis, D. and Wahlestedt, C. (1994) Cellular uptake of intracerebroventricularly administered biotin-or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. Cell. Mol. Neurobiol. 14, 475-485.
178. Yu, C., Brussaard, A. B., Yang, X., Listerud, M. and Role, L. W. (1993) Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons. Devl. Genet. 14, 296-304.
179. Yung, W. K. (1994) New approaches to molecular therapy of brain tumors. Curr. Opin. Neurol. 7, 501-505.
180. Zang, Z., Florijn, W. and Creese, I. (1994) Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochem. Pharmacol. 48, 225-228.
181. 2 receptors: behavioral correlates. Neurosci. Lett. 161, 223-226.
182. Zhang, S.-P., Nichols, R. A. and Weiss, B. (1994a) Oligodeoxynucleotides antisense to calmodulin mRNAs inhibit proliferation and NGF-induced differentiation of PC12 cells. Soc. Neurosci. 20, 1316.
183. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exptl. Therap. 271, 1462-1470.
184. 2 dopamine antisense oligodeoxynucleotide in mouse brain. J. Mol. Neurosci. 7, 13-28.
185. Zhou, L.-W., Moyer, J. A., Muth, E. A., Clark, B., Palkovits, M. and Weiss, B. (1985) Regional distribution of calmodulin activity in rat brain. J. Neurochem. 44, 1657-1662.
186. 2 dopamine receptors in mouse striatum. J. Pharmacol. Exptl. Therap. 268, 1015-1023.
187. Zon, G. (1995) Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Mol. Neurobiol. 10, 219-229.